da Costa Vanessa Duarte, Wiggers Wilian Jean, Ivantes Claudia Alexandra Pontes, da Fonseca Rodrigo Jardim Monteiro, Dávila Alberto Martín Rivera, Moreira Otacilio C, Ferreira Beatriz Iandra da Silva, de Paula Vanessa Salete, da Silva Lucas Lima, Santos Alanna Calheiros, Villar Livia Melo
Brazilian Reference Laboratory of Viral Hepatitis, Oswaldo Cruz Institute, Avenida Brasil, 4365, Manguinhos, Rio de Janeiro 21040-360, Brazil.
Service of Gastroenterology, Hepatology and Liver Transplantation, Hospital Nossa Senhora das Graças, R. Alcides Munhoz, 433, Mercês, Curitiba 80810-040, Brazil.
Pathogens. 2022 Sep 16;11(9):1054. doi: 10.3390/pathogens11091054.
The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has become a major public health worldwide. Hepatic dysfunction has been seen in patients with COVID-19 and could be related to a viral cytopathic effect, an exacerbated immune reaction, or drug-induced liver damage. Currently, routine modification of immunosuppressive therapy in patients with autoimmune hepatitis (AIH) before and after SARS-CoV-2 infection remains an important topic to be discussed. However, there is little evidence about this thematic to support any recommendation. Here, we described a case report in which the use of an immunosuppressive drug by a patient with diagnosed AIH might have influenced the COVID-19 clinical course with altered laboratory hematological and biochemical parameters during infection.
由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起的2019冠状病毒病（COVID-19）大流行已成为全球主要的公共卫生事件。COVID-19患者中出现了肝功能障碍，这可能与病毒细胞病变效应、加剧的免疫反应或药物性肝损伤有关。目前，自身免疫性肝炎（AIH）患者在感染SARS-CoV-2之前和之后常规调整免疫抑制治疗仍然是一个需要讨论的重要话题。然而，几乎没有证据支持这一主题下的任何建议。在此，我们描述了一例病例报告，其中一名确诊为AIH的患者使用免疫抑制药物可能影响了COVID-19的临床病程，感染期间实验室血液学和生化参数发生了变化。
